MindRank’s oral GLP-1 is the furthest along any AI-native drug programme
The Next Web
Read the full article
MindRank, a Hangzhou-based AI-driven drug developer, advanced its oral small-molecule GLP-1 receptor agonist MDR-001 to Phase III trials in about 4.5 years with $23 million in research spending. This candidate targets obesity and diabetes, aiming to offer a pill alternative to injectable GLP-1 drugs, potentially lowering costs and improving distribution. The company also secured $52 million in Series B funding and operates a platform integrating biological, chemical, computational, and clinical,
